Hemangioblastoma Market Research Report – Forecast to 2027

Global Hemangioblastoma Market: Information by Tumor Site (Brain, Spinal Cord, and Retina), Diagnosis (CT Scan, MRI Scan, and Others), Treatment (Surgery, Chemotherapy, Radiotherapy, Corticosteroids, Anticonvulsants, and Others)–Global Forecast Till 2027

ID: MRFR/Pharma/4943-HCR | | Region: Global | 100 pages

Market Scenario

The global hemangioblastoma market is expected to grow at the rate of 6.1% during the forecast period (2018–2023)

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.

Segmentation


The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.


On the basis of tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram.


The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into Conformal radiotherapy, Intensity-modulated radiotherapy (IMRT), Stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hemangioblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hemangioblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The hemangioblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemangioblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hemangioblastoma Market Share, by Region, 2017 (%)


Hemangioblastoma Market Share


Source: MRFR Analysis


The Americas are likely to dominate the global hemangioblastoma market owing to the adoption of highly advanced technology, the presence of a well-established healthcare system, rising prevalence of cancer, and increasing healthcare expenditure. According to the National cancer institute, in 2016, 15.5 million cancer cases were found in united states, and it is expected to reach 20.3 million by 2016. Also, the expenditure on cancer care in 2017 was 147.3 billion.


The European market is expected to be the second-largest hemangioblastoma market. The market growth in this region can be attributed to government funding and support of the healthcare sector and increasing cancer cases in the region. According to the European Commission, in 2016, The European nations (EU28), total expenditure of general governments on 'healthcare' amounted to 7.1 % of GDP and it was around USD1000 billion.


Asia-Pacific is expected to be the fastest-growing hemangioblastoma market during the forecast period owing to the increasing prevalence of chronic diseases, government support, rising investments in healthcare and presence of huge population. According to the World Economic Forum, in 2017, more than 55% of deaths occurred due to chronic and non-communicable diseases, which is more than 8 million and out of this one-third, people were below 60years.


The market in the Middle East & Africa is expected to account for the smallest share of the global hemangioblastoma market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.


Global Hemangioblastoma Market, by Tumor Site



  • Brain

  • Spinal Cord

  • Retina


Global Hemangioblastoma Market, by Diagnosis



  • CT Scan

  • MRI Scan

  • Angiogram


Global Hemangioblastoma Market, by Treatment



  • Surgery

  • Chemotherapy

  • Radiotherapy


    • Conformal Radiotherapy

    • Intensity Modulated Radiotherapy (IMRT)

    • Stereotactic Radiotherapy

    • Radiosurgery




  • Corticosteroids

    • Hydrocortisone

    • Dexamethasone

    • Methylprednisolone

    • Prednisolone



  • Anticonvulsants

    • Carbamazepine

    • Lamotrigine

    • Levetiracetam

    • Phenytoin

    • Sodium Valproate




Global Hemangioblastoma Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Middle East

  • Africa


Company Profiles    



  • Eli Lilly and Company

  • Bedford Laboratories

  • Astellas US Holding, Inc.

  • DNAtrix, Inc.

  • Advantagene, Inc

  • Burzynski Research Institute, Inc.

  • Direct Therapeutics, Inc.

  • Cellectar Biosciences, Inc.

  • Others


Intended Audience



  • Healthcare providers

  • Medical device manufacturers

  • Research institutes and academic centers

  • Contract research organizations (CROs)

  • Pharmaceutical companies

  • Government associations

  • Market research and consulting



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023:6.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Tumor Site, Diagnosis, And Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc
  Key Market Opportunities

  • Adoption of highly advanced technology
  • Presence of a well-established healthcare system
  •   Key Market Drivers   Growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure


    Frequently Asked Questions (FAQ) :


    Hemangioblastoma market CAGR would be 6.1% during the forecast period of 2020 to 2027.

    The hemangioblastoma market growth can be prevented by the rising cost of tumor treatment and lack of experts.

    The tumor sites are spinal cord tumor, brain tumor, and retinal tumor for the discussion of the hemangioblastoma market.

    The segments included are chemotherapy, surgery, corticosteroids, radiotherapy, and anticonvulsants.

    The Americas would lead the hemangioblastoma market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Hemangioblastoma Market, by Tumor Site

    6.1 Introduction

    6.2 Brain

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Spinal Cord

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Retina

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Hemangioblastoma Market, by Diagnosis

    7.1 Introduction

    7.2 CT scan

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 MRI Scan

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Angiogram

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Hemangioblastoma Market, by Treatment

    8.1 Introduction

    8.2 Surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Chemotherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Radiotherapy

    8.4.1 Conformal Radiotherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4.2 Intensity Modulated Radiotherapy (IMRT)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4.3 Stereotactic Radiotherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4.4 Radiosurgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5 Corticosteroids

    8.5.1 Hydrocortisone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5.2 Dexamethasone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5.3 Methylprednisolone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5.4 Prednisolone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6 Anticonvulsants

    8.6.1 Carbamazepine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6.2 Lamotrigine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6.3 Levetiracetam

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6.4 Phenytoin

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6.5 Sodium Valproate

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 9. Global Hemangioblastoma Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 South Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11. Company Profiles

    11.1 Eli Lilly and Company

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Bedford Laboratories

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Astellas US Holding, Inc.

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 DNAtrix, Inc.

    11.4.1 Company Overview

    11.4.2 Technology/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Advantagene, Inc

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Burzynski Research Institute, Inc.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Direct Therapeutics, Inc.

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Cellectar Biosciences, Inc.

    11.8.1 Overview

    11.8.2 Product/ Technology Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s Viewpoint

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Predictions for the Hemangioblastoma Industry

    Chapter 13. Appendix

    LIST OF TABLES

    Table 1 Global Hemangioblastoma Market Synopsis, 2020–2027

    Table 2 Global Hemangioblastoma Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Hemangioblastoma Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD Million)

    Table 5 Global Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD Million)

    Table 6 Global Hemangioblastoma Market, by Treatment, 2020–2027 (USD Million)

    Table 7 North America: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD

    Million)

    Table 8 North America: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 9 North America: Hemangioblastoma Market, by Treatment, 2020–2027 (USD

    Million)

    Table 10 US: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD Million)

    Table 11 US: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD Million)

    Table 12 US: Hemangioblastoma Market, by Treatment, 2020–2027 (USD Million)

    Table 13 Canada: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD Million)

    Table 14 Canada: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD Million)

    Table 15 Canada: Hemangioblastoma Market, by Treatment, 2020–2027 (USD

    Million)

    Table 16 South America: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD

    Million)

    Table 17 South America: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 18 South America: Hemangioblastoma Market, by Treatment, 2020–2027 (USD

    Million)

    Table 19 Europe: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD Million)

    Table 20 Europe: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD Million)

    Table 21 Europe: Hemangioblastoma Market, by Treatment, 2020–2027 (USD Million)

    Table 22 Western Europe: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD

    Million)

    Table 23 Western Europe: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 24 Western Europe: Hemangioblastoma Market, by Treatment, 2020–2027

    (USD Million)

    Table 25 Eastern Europe: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD

    Million)

    Table 26 Eastern Europe: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 27 Eastern Europe: Hemangioblastoma Market, by Treatment, 2020–2027

    (USD Million)

    Table 28 Asia-Pacific: Hemangioblastoma Market, by Tumor Site, 2020–2027 (USD

    Million)

    Table 29 Asia-Pacific: Hemangioblastoma Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 30 Asia-Pacific: Hemangioblastoma Market, by Treatment, 2020–2027 (USD

    Million)

    Table 31 Middle East & Africa: Hemangioblastoma Market, by Tumor Site, 2020–2027

    (USD Million)

    Table 32 Middle East & Africa: Hemangioblastoma Market, by Diagnosis, 2020–2027

    (USD Million)

    Table 33 Middle East & Africa: Hemangioblastoma Market, by Treatment, 2020–2027

    (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Hemangioblastoma Market

    Figure 3 Segmentation Market Dynamics for Global Hemangioblastoma Market

    Figure 4 Global Hemangioblastoma Market Share, by Tumor Site, 2020

    Figure 5 Global Hemangioblastoma Market Share, by Diagnosis, 2020

    Figure 6 Global Hemangioblastoma Market Share, by Treatment, 2020

    Figure 7 Global Hemangioblastoma Market Share, by Region, 2020

    Figure 8 North America: Hemangioblastoma Market Share, by Country, 2020

    Figure 9 Europe: Hemangioblastoma Market Share, by Country, 2020

    Figure 10 Asia-Pacific: Hemangioblastoma Market Share, by Country, 2020

    Figure 11 Middle East & Africa: Hemangioblastoma Market Share, by Country, 2020

    Figure 12 Global Hemangioblastoma Market: Company Share Analysis, 2020 (%)

    Figure 13 Eli Lilly and Company: Key Financials

    Figure 14 Eli Lilly and Company: Segmental Revenue

    Figure 15 Eli Lilly and Company: Geographical Revenue

    Figure 16 Bedford Laboratories: Key Financials

    Figure 17 Bedford Laboratories: Segmental Revenue

    Figure 18 Bedford Laboratories: Geographical Revenue

    Figure 19 Astellas US Holding, Inc.: Key Financials

    Figure 20 Astellas US Holding, Inc.: Segmental Revenue

    Figure 21 Astellas US Holding, Inc.: Geographical Revenue

    Figure 22 DNAtrix, Inc.: Key Financials

    Figure 23 DNAtrix, Inc.: Segmental Revenue

    Figure 24 DNAtrix, Inc.: Geographical Revenue

    Figure 25 Advantagene, Inc: Key Financials

    Figure 26 Advantagene, Inc: Segmental Revenue

    Figure 27 Advantagene, Inc. Geographical Revenue

    Figure 28 Burzynski Research Institute, Inc.: Key Financials

    Figure 29 Burzynski Research Institute, Inc.: Segmental Revenue

    Figure 30 Burzynski Research Institute, Inc.: Geographical Revenue

    Figure 31 Direct Therapeutics, Inc.: Key Financials

    Figure 32 Direct Therapeutics, Inc.: Segmental Revenue

    Figure 33 Direct Therapeutics, Inc.: Geographical Revenue

    Figure 34 Cellectar Biosciences, Inc.: Key Financials

    Figure 35 Cellectar Biosciences, Inc.: Segmental Revenue

    Figure 36 Cellectar Biosciences, Inc.: Geographical Revenue

    Figure 37 Commonwealth Serum Laboratories (CSL): Key Financials